Encephalitis Induced by Durvalumab During Treatment of Metastatic Small-Cell Lung Cancer: Illustrative Case and Review of the Literature
This report describes a 66-year-old female who received Durvalumab for metastatic small-cell lung cancer. Following 3 cycles of treatment, she developed encephalitis.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
More News: Allergy & Immunology | Brain | Cancer | Cancer & Oncology | Chemotherapy | Encephalitis | Immunotherapy | Lung Cancer | Neurology | Statistics | Study